AYTU BIOPHARMA, INC Proceeds from Issuance or Sale of Equity
AYTU BIOPHARMA, INC (AYTU) reported Proceeds from Issuance or Sale of Equity of $86.00 thousand for the 9-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2024-05-15
- AYTU BIOPHARMA, INC proceeds from issuance or sale of equity for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC proceeds from issuance or sale of equity for the quarter ending 2023-03-31 was $1.44M.
- AYTU BIOPHARMA, INC proceeds from issuance or sale of equity for the quarter ending 2019-06-30 was $0.00.
- AYTU BIOPHARMA, INC proceeds from issuance or sale of equity for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC proceeds from issuance or sale of equity for fiscal 2019 was $15.18M, a 28.21% increase from fiscal 2018.
- AYTU BIOPHARMA, INC proceeds from issuance or sale of equity for fiscal 2018 was $11.84M.
- AYTU BIOPHARMA, INC proceeds from issuance or sale of equity for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- AYTU BIOPHARMA, INC proceeds from issuance or sale of equity for fiscal 2016 was $200.00K.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 9 month as first filed | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $86.00K 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $86.00K 10-Q · filed 2024-02-14 | ||||
| 2023-03-31 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $13.01M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $11.57M 10-Q · filed 2024-02-14 | ||||
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $0.00 derived: sum of 2 quarters · filed 2019-09-26 | $15.18M 10-K · filed 2019-09-26 | ||
| 2019-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-14 | $15.18M 10-Q · filed 2019-05-14 | |||
| 2018-12-31 | $15.18M 10-Q · filed 2019-05-14 | ||||
| 2018-06-30 | -$12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $0.00 derived: sum of 2 quarters · filed 2019-09-26 | $0.00 derived: sum of 3 quarters · filed 2019-09-26 | $11.84M 10-K · filed 2019-09-26 | |
| 2018-03-31 | $12.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-14 | $12.90M derived: sum of 2 quarters · filed 2019-05-14 | $24.74M 10-Q · filed 2019-05-14 | $11.84M 10-Q · filed 2018-05-14 | $24.74M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-14 | $11.84M 10-Q · filed 2019-05-14 | $11.84M derived: sum of 3 quarters · filed 2019-05-14 | ||
| 2017-09-30 | $11.84M 10-Q · filed 2018-11-07 | $11.84M derived: sum of 2 quarters · filed 2018-11-07 | |||
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $0.00 10-K · filed 2017-08-31 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-11 | ||||
| 2016-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $200.00K 10-K · filed 2017-08-31 | |||
| 2016-03-31 | $200.00K 10-Q · filed 2017-05-11 | ||||
| 2015-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-01 | $0.00 10-K · filed 2016-09-01 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |